# Valuation Framework

**Last Updated:** 2025-11-17
**Status:** Draft - Needs mentor validation (Nov 27)

---

## Core Valuation Thesis: TRL 7-8 De-Risked Technology

### Why This Matters

**Traditional Early-Stage Startup:**
- Investors fund R&D risk (will the tech work?)
- Market risk (will customers buy?)
- Execution risk (can the team deliver?)
- **Typical Valuation:** $2M-$5M pre-money

**Luminous Position:**
- âœ… **Technology risk DE-RISKED:** TRL 7-8, proven with customer data
- ðŸ”´ **Market risk REMAINING:** Will operators deploy and pay?
- ðŸ”´ **Execution risk REMAINING:** Can we scale to 3-4 sites?
- **Justified Valuation:** $7M-$10M pre-money (HYPOTHESIS - needs mentor validation)

**Investor Value Proposition:**
"You're not funding technology development. You're funding **market expansion of proven technology**. We've already invested $[TBD] to reach TRL 7-8. You're buying de-risked execution."

---

## Investment to Date (To Be Documented)

### Capital Invested

**Founder Cash Investment:**
- Jeff Violo: $[TBD]
- Greg Saunders (CTO): $[TBD]
- Shawn Lewenza (CSO): $[TBD]
- **Total Cash:** $[TBD]

**Sweat Equity (Opportunity Cost):**
- Jeff Violo (COO): [X] months at market rate $[TBD]/year = $[TBD]
- Greg Saunders (CTO): [X] months at market rate $[TBD]/year = $[TBD]
- Shawn Lewenza (CSO): [X] months at market rate $[TBD]/year = $[TBD]
- **Total Sweat Equity:** $[TBD]

**Total Investment to Reach TRL 7-8:** $[TBD]

---

### IP & Technology Developed

**Biosensor Technology:**
- 3-panel system (atuA, marR, p3680) developed and validated
- 92% OSPW success rate, R > 0.9 HRMS correlation
- 24-72 hour results (vs. 2-4 weeks HRMS)
- Validated with Imperial Kearl field data (98-day wetland pilot)

**Confluent Platform:**
- AI-native architecture (TerminusDB graph database)
- Model-agnostic orchestration (Claude, GPT-4, specialized models)
- Unified structured + unstructured data (biosensor + PDFs + SCADA + weather)
- Natural language query interface
- Automated correlation and pattern matching

**Operational Intelligence Framework:**
- 5 operational scenarios documented with quantified value ($260K/year)
- 95-99% time-to-decision reduction proven
- Integration thesis validated (biosensor + Confluent > sum of parts)

**Customer Validation:**
- Imperial Kearl data analysis (1-hectare wetland, Orbitrap MS validation)
- CNRL pilot discussions advanced
- Suncor potential engagement (via Michael Lipsett mentor connection)

---

## TRL Status Validation

### Current TRL Assessment

**Biosensor (TRL 7-8):**
- **TRL 7:** System prototype demonstrated in operational environment
  - âœ… Analyzed field samples from Imperial Kearl operational wetland
  - ðŸ”´ Not yet deployed on-site (lab-based analysis)
- **TRL 8:** System complete and qualified through test and demonstration
  - ðŸ”´ Requires on-site deployment to achieve

**Current Status: TRL 7** (field sample validation, not yet on-site deployment)

**Confluent Platform (TRL 6-7):**
- **TRL 6:** System/subsystem model or prototype demonstrated in relevant environment
  - âœ… Functional platform with real Kearl data
  - âœ… Natural language queries generating operational insights
- **TRL 7:** System prototype demonstrated in operational environment
  - ðŸ”´ Requires operator using platform for real decisions to achieve

**Current Status: TRL 6-7** (functional with real data, not yet driving operational decisions)

**Integrated System (TRL 7):**
- Biosensor + Confluent validated with Kearl field data
- Operational scenarios documented showing decision-making value
- Ready for pilot deployment to achieve TRL 8

---

### What TRL 7 De-Risks for Investors

**Technology Risk: SIGNIFICANTLY REDUCED**
- Biosensor works (proven correlation with gold standard HRMS)
- Confluent platform functional (generates insights from real operator data)
- Integration proven (time-to-decision reduction quantified)

**Remaining Risk: MARKET & EXECUTION**
- Will operators deploy and pay? (Pilot #1 de-risks this)
- Can we scale to 3-4 sites simultaneously? (Team/execution risk)
- Will pilots convert to subscriptions? (Commercial model risk)

**Investor Pitch:**
"We've solved the hard technology problem on our own dime. You're funding the easier commercial scale-up problem."

---

## Valuation Scenarios

### Scenario A: Pre-Pilot Signature (NOW - Dec 2025)

**What We Have:**
- TRL 7 technology with customer validation
- CNRL pilot discussions advanced (not signed)
- $260K ROI validated from Kearl data
- Competitive moat documented (2-3 year barrier to entry)

**Comparable Valuation:**
- Early-stage clean tech with proven prototype: $5M-$7M pre-money
- Strong team + customer validation: +20-30% premium

**Realistic Pre-Money Valuation:** $5M-$7M
- $1.5M raise â†’ 21-30% dilution

**Pros:** Capital in hand to execute pilots confidently
**Cons:** Higher dilution, lower valuation

---

### Scenario B: Post-Pilot Signature (Q2 2026)

**What We Have:**
- TRL 7 technology with customer validation
- CNRL pilot agreement signed ($130K ARR)
- Deployment starting (moves toward TRL 8)
- Paying customer = revenue traction

**Comparable Valuation:**
- Pre-revenue â†’ early revenue transition: $8M-$12M pre-money
- Paying customer significantly de-risks market adoption

**Realistic Pre-Money Valuation:** $8M-$12M
- $1.5M raise â†’ 12-18% dilution

**Pros:** Lower dilution, higher valuation
**Cons:** Burns 6 months runway, must execute perfectly

---

### Scenario C: Post-Pilot Success (Q4 2026)

**What We Have:**
- TRL 8 technology (deployed and demonstrating value)
- $130K ARR from CNRL pilot
- 2nd pilot in advanced discussions
- Proven commercial model (pilot â†’ subscription pathway validated)

**Comparable Valuation:**
- Early revenue with proven model: $12M-$20M pre-money
- Multiple customer traction + subscription model proven

**Realistic Pre-Money Valuation:** $12M-$20M
- $1.5M raise â†’ 7-12% dilution

**Pros:** Lowest dilution, highest valuation
**Cons:** Runway critically low, may need bridge financing

---

## Capital Efficiency Story

### Bootstrapped to TRL 7 (Competitive Advantage)

**Comparable Startups:**
- Typical clean tech raises $3M-$5M seed to reach TRL 6-7
- Often 10+ person teams, high burn rate ($200K-$500K/month)

**Luminous:**
- Bootstrapped to TRL 7 on $[TBD] invested capital
- Lean team (3 co-founders + minimal burn: $7.5K/month)
- Customer validation achieved without sales team (operator relationships)

**Valuation Argument:**
"We've proven we can execute efficiently. $1.5M goes 20x farther with this team than typical early-stage startup burn rate."

---

## Mentor Validation Questions (Nov 27)

### For Terence Tham / Dave Lee (Commercial Strategy):

1. **Valuation Reality Check:**
   - Is $7M-$10M pre-money defensible for TRL 7 + customer validation but pre-revenue?
   - What do clean tech / SaaS companies at similar stage actually raise at?

2. **Timing Strategy:**
   - Should we raise NOW at $5M-$7M (higher dilution, confident execution)?
   - Or bootstrap to pilot signature and raise at $8M-$12M (lower dilution, tighter runway)?

3. **Capital Efficiency:**
   - How do we pitch "bootstrapped to TRL 7" as competitive advantage?
   - Does low burn rate + lean team support higher valuation multiples?

### For Jocelyn McMinn / Doug Beach (Operator Context):

1. **Market De-Risking:**
   - Does TRL 7 with customer validation meaningfully de-risk adoption for operators?
   - Would operators view us differently than early-stage tech (more credible, worth paying for)?

2. **Pilot Signature Impact:**
   - How much does signed pilot agreement change investor perception?
   - Is gap between "advanced discussions" and "signed agreement" critical for valuation?

---

## Next Steps

1. **Document Investment to Date** (by Nov 27)
   - Founder cash invested
   - Sweat equity calculation (opportunity cost)
   - Total capital to reach TRL 7

2. **Validate TRL Claims** (with Greg/Shawn)
   - Confirm biosensor = TRL 7 (field samples, not on-site deployment)
   - Confirm Confluent = TRL 6-7 (functional, not yet driving operator decisions)

3. **Refine Scenarios** (post-mentor call)
   - Adjust valuation ranges based on mentor feedback
   - Decide timing (raise now vs. post-pilot signature)

4. **Prepare Investor Pitch** (Week 5-8)
   - "Funding market expansion, not technology development"
   - Capital efficiency story (bootstrapped to TRL 7)
   - De-risked technology + remaining execution risk

---

**Status:** Ready for mentor validation (Nov 27)
**Owner:** Jeff Violo
**Next Update:** Post-mentor call (incorporate valuation feedback)
